Haemonetics Corporation
NYSE:HAE · New York Stock Exchange
+$0.84 today
Vol 0.89M · Avg 0.88M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NYSE:HAE · Revenue to Net Income
Key Ratios
Analysis
$1.3B of revenue converted into $97.3M of net income for the selected period. Gross margin is 57.4% and net margin is 7.4%, showing how much revenue survives after costs and taxes. EPS is $2.02, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3B -2.0% | $1.4B +4.0% | $1.3B +12.0% | $1.2B +17.7% | $993.2M | $1.0B | $809.6M | $921.6M |
| Cost of Revenue | $590.4M +1.4% | $582.3M -2.5% | $597.1M +9.4% | $545.8M +18.0% | $462.4M | $344.8M | $725.6M | $804.0M |
| Gross Profit | $743.6M -4.5% | $778.5M +9.4% | $711.9M +14.3% | $622.9M +17.4% | $530.8M | $10.3B | $8.9B | $7.6B |
| Gross Margin | 55.7% -1.5pp | 57.2% +2.8pp | 54.4% +1.1pp | 53.3% -0.1pp | 53.4% | 45.5% | 9.8% | 28.9% |
| Research & Development | $59.8M -13.9% | $69.4M +10.1% | $63.0M +7.5% | $58.6M +6.2% | $55.2M | $378.4M | $983.2M | $1.3B |
| Selling, General & Admin | $442.4M +4.8% | $422.1M +0.3% | $420.8M +12.5% | $374.0M +12.6% | $332.2M | $1.4B | $620.6M | $923.0M |
| Operating Expenses | $502.2M -9.8% | $556.7M +1.8% | $547.0M +17.2% | $466.8M +3.7% | $450.0M | $3.6B | $5.3B | $7.0B |
| Depreciation & Amortization | $155.7M +43.0% | $108.9M +22.9% | $88.6M +4.5% | $84.8M -2.0% | $86.5M | $1.2B | $374.2M | $1.2B |
| EBITDA | $312.4M -12.2% | $356.0M +20.5% | $295.5M +17.2% | $252.0M +31.4% | $191.7M | $12.6B | -$15.2B | $6.8B |
| EBITDA Margin | 23.4% -2.7pp | 26.2% +3.6pp | 22.6% +1.0pp | 21.6% +2.3pp | 19.3% | 10.0% | 5.6% | 46.3% |
| Operating Income | $241.4M +8.8% | $221.8M +34.5% | $164.9M +5.7% | $156.0M +93.2% | $80.8M | $10.6B | $12.3B | $14.0B |
| Operating Margin | 18.1% +1.8pp | 16.3% +3.7pp | 12.6% -0.8pp | 13.4% +5.2pp | 8.1% | 18.7% | 16.6% | 24.1% |
| Interest Income | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.5B | -$1.6B |
| Interest Expense | $28.7M +194.5% | $9.7M -25.1% | $13.0M -11.0% | $14.6M -14.5% | $17.1M | $969.2M | $1.1B | $1.0B |
| Other Income / Expenses | -$113.4M -1063.3% | -$9.7M +25.1% | -$13.0M +11.0% | -$14.6M +14.5% | -$17.1M | -$1.6B | -$1.5B | $1.4B |
| Income Before Tax | $128.0M -39.6% | $212.1M +39.6% | $151.9M +7.4% | $141.4M +122.2% | $63.6M | -$15.6B | $3.3B | $4.9B |
| Pre-Tax Margin | 9.6% -6.0pp | 15.6% +4.0pp | 11.6% -0.5pp | 12.1% +5.7pp | 6.4% | 13.3% | 20.8% | 18.7% |
| Income Tax Expense | $30.7M -30.8% | $44.4M +29.4% | $34.3M +31.9% | $26.0M +28.4% | $20.3M | $666.8M | $1.3B | -$1.6B |
| Net Income | $97.3M -42.0% | $167.7M +42.6% | $117.6M +1.9% | $115.4M +166.1% | $43.4M | $5.0B | $4.9B | $4.8B |
| Net Margin | 7.3% -5.0pp | 12.3% +3.3pp | 9.0% -0.9pp | 9.9% +5.5pp | 4.4% | 7.4% | 12.4% | 17.5% |
| EPS (Basic) | $2 -38.1% | $3 +42.7% | $2 +2.2% | $2 +167.1% | $1 | $1.2B | $400.8M | $703.2M |
| EPS (Diluted) | $2 -38.1% | $3 +44.5% | $2 +2.2% | $2 +166.7% | $1 | $620.6M | $766.2M | $609.4M |
| Weighted Avg Shares | $47.2M -6.3% | $50.3M -0.7% | $50.7M -0.2% | $50.8M -0.5% | $51.0M | $892.2M | $757.8M | $925.8M |
| Weighted Avg Shares (Diluted) | $47.4M -6.7% | $50.7M -1.3% | $51.4M -0.0% | $51.4M +0.1% | $51.4M | $319.6M | $1.2B | $924.4M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Catalyst Pharmaceuticals, Inc.
NASDAQ:CPRX
$3.84B
Concentra Group Holdings Parent, Inc.
NYSE:CON
$3.65B
Beam Therapeutics Inc.
NASDAQ:BEAM
$3.38B
Integer Holdings Corporation
NYSE:ITGR
$3.08B
Warby Parker Inc.
NYSE:WRBY
$3.07B
Premier, Inc.
PINC
$2.34B
LeMaitre Vascular, Inc.
NASDAQ:LMAT
$2.14B
DENTSPLY SIRONA Inc.
NASDAQ:XRAY
$2.04B
Bausch Health Companies Inc.
NYSE:BHC
$1.71B
QuidelOrtho Corporation
NASDAQ:QDEL
$903.87M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does HAE generate?
Haemonetics Corporation (HAE) reported $1.33B of revenue in fiscal 2026.
Is HAE profitable?
Haemonetics Corporation (HAE) reported $97.31M of net income, with a net margin of 7.3%.
Explore More
Continue the stock analysis
Jump to another research area for this company.